<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Few therapeutic strategies exist for <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> relapsing post allogeneic hematopoietic cell transplantation </plain></SENT>
<SENT sid="1" pm="."><plain>We present outcomes on 35 patients with nonchronic myelogenous <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e>, the majority having <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) or <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>/<z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> (<z:e sem="disease" ids="C1301355" disease_type="Neoplastic Process" abbrv="">MDS/MPD</z:e>) (n = 22) receiving lymphodepleting chemotherapy followed by donor lymphocyte infusion (DLI) at 2 T cell dose levels (0.5 and 1.0 × 10(8) CD3/kg) </plain></SENT>
<SENT sid="2" pm="."><plain>Forty-nine percent of patients achieved complete remission (CR), with a median duration of remission of 6 months (range: 2-71+) </plain></SENT>
<SENT sid="3" pm="."><plain>CR rates were similar between the 2 groups </plain></SENT>
<SENT sid="4" pm="."><plain>The incidence of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (aGVHD) of any grade was 49% </plain></SENT>
<SENT sid="5" pm="."><plain>We saw a higher incidence of grade II-IV aGVHD, with a rate of 66% using the higher-dose DLI (grade III, 33% and grade 4, 20%) versus only 25% (10% grade III-IV) with the lower-dose DLI (P = .06) </plain></SENT>
<SENT sid="6" pm="."><plain>Overall survival at 1 and 2 years was 30% (95% confidence interval [CI], 16%-45%) and 19% (95% CI, 8%-34%); however, for those achieving CR, 1- and 2-year survival was improved at 44% (95% CI, 20%-66%) and 28% (95% CI, 8%-52%) (P = .03), respectively </plain></SENT>
<SENT sid="7" pm="."><plain>These results demonstrate that DLI after lymphodepleting chemotherapy for <z:e sem="disease" ids="C1335737" disease_type="Neoplastic Process" abbrv="">relapsed hematologic malignancies</z:e> results in frequent CRs </plain></SENT>
<SENT sid="8" pm="."><plain>The lower DLI dose regimen improved the tolerability of this therapeutic approach, with modest rates of severe aGVHD </plain></SENT>
</text></document>